Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cannabigerol + cannabinol + cannabichromene
- Development stage
- Preclinical
- Lead developer
- Avecho Biotechnology
- Modality
- Small Molecules
- Administration
- Oral, Sublingual, Oromucosal, Inhalation, Topical, Rectal, Intraperitoneal
01
Overview
Cannabigerol + cannabinol + cannabichromene is a pharmaceutical combination of minor cannabinoids being developed by Avecho Biotechnology. This product leverages Avecho's proprietary Tocopherol Phosphate Mixture (TPM) technology, a delivery system derived from Vitamin E designed to enhance the solubility and absorption of lipophilic small molecules. The combination targets the endocannabinoid system by modulating the activity of Cannabinoid receptor 1 (CB1) and Cannabinoid receptor 2 (CB2). While Avecho's pipeline currently lists this product for unspecified future indications, it represents an expansion of their cannabinoid portfolio beyond CBD and THC into minor cannabinoids with distinct pharmacological profiles.
- Other names
- Minor cannabinoids
02
Targets
ADRA2A (α2A)PPARG (Peroxisome proliferator-activated receptor gamma)CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on cannabigerol + cannabinol + cannabichromene.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cannabigerol + cannabinol + cannabichromene.